Dutch healthtech Ditto raises €7.6M to bring AI-powered patient support across Europe

Dutch healthtech Ditto raises €7.6M to bring AI-powered patient support across Europe


Dutch healthtech startup Ditto has raised €7.6 million to
support its European expansion and further develop its AI-powered patient
communication platform. 
The funding round was led by Heal Capital, with
participation from Optiverder 
and Rubio Impact
Ventures. Since launching last summer, the app has been downloaded by nearly
100,000 users.

Ditto was founded by Tobias Polak, Bart Voorn, and Merlijn van Breugel. The company aims to address a common challenge in healthcare
communication: many patients leave medical consultations without fully
understanding or remembering what was discussed.

The app allows patients to record consultations or upload
photographs of medical letters. Using AI, Ditto generates summaries that can be
revisited later and translated into simplified language or other languages, including English, Turkish, and Arabic. Users can also securely share summaries
with family members, while the company says no data is stored centrally.

Tobias Polak, co-founder of Ditto, noted that medical
consultations are often short, and patients may struggle to fully process or
remember important information, particularly when receiving difficult news:

We are trying to
shift healthcare thinking away from institutions and towards the patient
experience. Our ambition is to help people better understand their care journey
during some of the most vulnerable moments in life.

The company says the platform is designed not only to
improve patient understanding and engagement but also to reduce repetitive
follow-up questions and administrative pressure on healthcare professionals.

The newly raised capital will be used to expand Ditto
across Europe and develop additional patient support features, including tools
designed to help users prepare for consultations and navigate treatment and
care journeys together with family members.



Source link

Leave a Reply